Young-Hoo Kim1, Jun-Shik Kim, Wansoo Huh, Kwang-Hoon Lee. 1. The Joint Replacement Center of Korea, Ewha Womans University School of Medicine, 911-1 MokDong, YangCheon-Gu, Seoul 158-710, Korea. younghookim@ewha.ac.kr
Abstract
BACKGROUND: The greater lubricity and resistance to scratching of oxidized zirconium femoral components are expected to result in less polyethylene wear than cobalt-chrome femoral components. QUESTIONS/PURPOSES: We examined polyethylene wear particles in synovial fluid and compared the weight, size (equivalent circle diameter), and shape (aspect ratio) of polyethylene wear particles in knees with an oxidized zirconium femoral component with those in knees with a cobalt-chrome femoral component. PATIENTS AND METHODS: One hundred patients received anoxidized zirconium femoral component in one knee and a cobalt-chrome femoral component in the other. There were 73 women and 27 men with a mean age of 55.6 years (range, 44-60 years). The minimum followup was 5 years (mean, 5.5 years; range, 5-6 years). Polyethylene wear particles were analyzed using thermogravimetric methods and scanning electron microscopy. RESULTS: The weight of polyethylene wear particles produced at the bearing surface was 0.0223 +/- 0.0054 g in 1 g synovial fluid in patients with an oxidized zirconium femoral component and 0.0228 +/- 0.0062 g in patients with a cobalt-chrome femoral component. Size and shape of polyethylene wear particles were 0.59 +/- 0.05 microm and 1.21 +/- 0.24, respectively, in the patients with an oxidized zirconium femoral component and 0.52 +/- 0.03 microm and 1.27 +/- 0.31, respectively, in the patients with a cobalt-chrome femoral component. Knee Society knee and function scores, radiographic results, and complication rate were similar between the knees with an oxidized zirconium and cobalt-chrome femoral component. CONCLUSIONS: The weight, size, and shape of polyethylene wear particles were similar in the knees with an oxidized zirconium and a cobalt-chrome femoral component. We found the theoretical advantages of this surface did not provide the actual advantage. LEVEL OF EVIDENCE: Level I, therapeutic study. See the guidelines for Authors for a complete description of levels of evidence.
RCT Entities:
BACKGROUND: The greater lubricity and resistance to scratching of oxidized zirconium femoral components are expected to result in less polyethylene wear than cobalt-chrome femoral components. QUESTIONS/PURPOSES: We examined polyethylene wear particles in synovial fluid and compared the weight, size (equivalent circle diameter), and shape (aspect ratio) of polyethylene wear particles in knees with an oxidized zirconium femoral component with those in knees with a cobalt-chrome femoral component. PATIENTS AND METHODS: One hundred patients received an oxidized zirconium femoral component in one knee and a cobalt-chrome femoral component in the other. There were 73 women and 27 men with a mean age of 55.6 years (range, 44-60 years). The minimum followup was 5 years (mean, 5.5 years; range, 5-6 years). Polyethylene wear particles were analyzed using thermogravimetric methods and scanning electron microscopy. RESULTS: The weight of polyethylene wear particles produced at the bearing surface was 0.0223 +/- 0.0054 g in 1 g synovial fluid in patients with an oxidized zirconium femoral component and 0.0228 +/- 0.0062 g in patients with a cobalt-chrome femoral component. Size and shape of polyethylene wear particles were 0.59 +/- 0.05 microm and 1.21 +/- 0.24, respectively, in the patients with an oxidized zirconium femoral component and 0.52 +/- 0.03 microm and 1.27 +/- 0.31, respectively, in the patients with a cobalt-chrome femoral component. Knee Society knee and function scores, radiographic results, and complication rate were similar between the knees with an oxidized zirconium and cobalt-chrome femoral component. CONCLUSIONS: The weight, size, and shape of polyethylene wear particles were similar in the knees with an oxidized zirconium and a cobalt-chrome femoral component. We found the theoretical advantages of this surface did not provide the actual advantage. LEVEL OF EVIDENCE: Level I, therapeutic study. See the guidelines for Authors for a complete description of levels of evidence.
Authors: Victoria Good; Michael Ries; Robert L Barrack; Kirstin Widding; Gordon Hunter; Dan Heuer Journal: J Bone Joint Surg Am Date: 2003 Impact factor: 5.284
Authors: Matthew B Collier; C Anderson Engh; Kyle M Hatten; Stuart D Ginn; Todd M Sheils; Gerard A Engh Journal: J Bone Joint Surg Am Date: 2008-07 Impact factor: 5.284
Authors: Peter F Sharkey; William J Hozack; Richard H Rothman; Shani Shastri; Sidney M Jacoby Journal: Clin Orthop Relat Res Date: 2002-11 Impact factor: 4.176
Authors: Michael R O'Rourke; John J Callaghan; Devon D Goetz; Patrick M Sullivan; Richard C Johnston Journal: J Bone Joint Surg Am Date: 2002-08 Impact factor: 5.284
Authors: Thomas J Heyse; Marcella E Elpers; Danyal H Nawabi; Timothy M Wright; Steven B Haas Journal: Clin Orthop Relat Res Date: 2014-01 Impact factor: 4.176